In India, melanoma predominantly affects the soles of feet and nail beds—areas often overlooked in standard screenings. While breakthrough treatments exist, late diagnosis remains a critical barrier to survival.
- Melanoma in India frequently presents as Acral Lentiginous Melanoma on soles and nails.
- Common misdiagnosis occurs as fungal infections or diabetic ulcers.
- Advanced therapies like mRNA vaccines and checkpoint inhibitors are highly effective if caught early.
Thousands of patients in India are diagnosed with melanoma every year. While less prevalent than in Western nations, its presentation in the Indian population makes early detection uniquely challenging. A dangerous gap exists: while treatment options have become more powerful and personalised, patients typically arrive at clinics when the disease is already advanced.
The Blind Spot in Diagnosis
Most global awareness campaigns focus on fairer-skinned populations, where melanoma appears as irregular moles on sun-exposed skin. This narrative is misleading for Indian patients. In India, Acral Lentiginous Melanoma accounts for 35% to 60% of cases. This subtype manifests on the soles of the feet or beneath the nails—sites rarely examined during routine check-ups.
These lesions are frequently mistaken for simple bruises, fungal infections, or diabetic ulcers. By the time a biopsy is performed, the cancer has often metastasized. Furthermore, mucosal melanomas, which start in mucous membranes, are highly aggressive and often remain undetected until they spread.
A Decade of Therapeutic Transformation
The landscape of oncology has shifted dramatically. The discovery of CTLA-4 and PD-1 by James Allison and Tasuku Honjo, which earned them the 2018 Nobel Prize, introduced immune-checkpoint blockade. Instead of attacking the tumor directly, this therapy releases the 'biological brakes' of the patient's own immune system.
Any pigmented lesion that changes or persists, wherever it appears on the body, deserves investigation rather than reassurance.
Precision medicine has further refined care. Through Next-Generation Sequencing (NGS), doctors can now target specific mutations in the BRAF pathway. Most recently, in August 2026, the use of intismeran (a personalised mRNA vaccine) combined with pembrolizumab showed a significant reduction in recurrence for high-risk patients.
Why This Matters
BozokMedia analysis shows a systemic failure in the referral pipeline. The sophistication of mRNA vaccines and TIL therapy is irrelevant if the diagnostic window is missed. India requires a national melanoma registry and a fundamental shift in primary care training to recognize non-traditional presentations of skin cancer.
| Feature | Western Melanoma | Indian Melanoma |
|---|---|---|
| Primary Location | Sun-exposed areas/Moles | Soles, Nails, Mucosa |
| Common Appearance | Irregular pigmented mole | Ulcer or bruise-like lesion |
| Dominant Subtype | Cutaneous Melanoma | Acral Lentiginous Melanoma |
Frequently Asked Questions
1. Should I worry about a dark spot on my foot?
If the spot is changing in size, shape, or color, or if it persists despite treatment for fungus/injury, seek an immediate biopsy.
2. How does a personalized mRNA vaccine work for cancer?
It is built from the patient's own tumor sequence to train the immune system to recognize and destroy remaining cancer cells after surgery.
